Compare Solaredge Technologies Inc (SEDG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Solaredge Technologies Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Solaredge Technologies Inc trades at $32.21 (market cap $2.00B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 5.1× Solaredge Technologies Inc's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Solaredge Technologies Inc for 34 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SEDG | XBI | |
|---|---|---|
Market Cap | $2.00B | $10.11B |
Volume | 2,739,860 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $78.51 | $169.55 |
52-Week Low | $28.47 | $104.99 |
Typical Hold Time | 34 Days | 38 Days |
Enterprise Value | $1.86B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SolarEdge Technologies (SEDG) trades at $32.47, down 2.08% amid bearish technical signals and ongoing financial challenges. The company reported a net loss of $405 million in 2025 with negative profit margins, though revenue showed some recovery to $1.18 billion. Recent news highlights multiple law firm investigations into investor claims while the company pursues AI data center expansion opportunities.
The outlook remains challenging with significant execution risks and negative profitability, though analyst consensus suggests modest upside potential to the $37.75 price target. Key risks include ongoing legal scrutiny, competitive pressures in solar markets, and the company's ability to achieve its ambitious 2029 revenue target of $2.4 billion.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
